Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129


Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models.

Melchor L, Molyneux G, Mackay A, Magnay FA, Atienza M, Kendrick H, Nava-Rodrigues D, López-García MÁ, Milanezi F, Greenow K, Robertson D, Palacios J, Reis-Filho JS, Smalley MJ.

J Pathol. 2014 Jun;233(2):124-37. doi: 10.1002/path.4345.


Tip30 controls differentiation of murine mammary luminal progenitor to estrogen receptor-positive luminal cell through regulating FoxA1 expression.

Chen F, Li A, Gao S, Hollern D, Williams M, Liu F, VanSickle EA, Andrechek E, Zhang C, Yang C, Luo R, Xiao H.

Cell Death Dis. 2014 May 22;5:e1242. doi: 10.1038/cddis.2014.224.


Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.

Wang S, Liu JC, Kim D, Datti A, Zacksenhaus E.

Breast Cancer Res. 2016 Jan 19;18(1):9. doi: 10.1186/s13058-015-0668-y.


Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.

Van Keymeulen A, Lee MY, Ousset M, Brohée S, Rorive S, Giraddi RR, Wuidart A, Bouvencourt G, Dubois C, Salmon I, Sotiriou C, Phillips WA, Blanpain C.

Nature. 2015 Sep 3;525(7567):119-23. doi: 10.1038/nature14665. Epub 2015 Aug 12.


Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.

Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM.

Breast Cancer Res. 2010;12(5):R68. doi: 10.1186/bcr2635. Epub 2010 Sep 2.


RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells.

van Bragt MP, Hu X, Xie Y, Li Z.

Elife. 2014 Nov 21;3:e03881. doi: 10.7554/eLife.03881.


Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells.

Pires MM, Hopkins BD, Saal LH, Parsons RE.

Cancer Biol Ther. 2013 Mar;14(3):246-53. doi: 10.4161/cbt.23297. Epub 2013 Jan 4.


Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.

Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, Harrell JC, Roman E, Adamo B, Troester M, Perou CM.

Breast Cancer Res Treat. 2013 Nov;142(2):237-55. doi: 10.1007/s10549-013-2743-3. Epub 2013 Oct 27.


The cell of origin of BRCA1 mutation-associated breast cancer: a cautionary tale of gene expression profiling.

Molyneux G, Smalley MJ.

J Mammary Gland Biol Neoplasia. 2011 Apr;16(1):51-5. doi: 10.1007/s10911-011-9202-8. Epub 2011 Feb 19. Review.


Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype.

Lu S, Singh K, Mangray S, Tavares R, Noble L, Resnick MB, Yakirevich E.

Mod Pathol. 2013 Apr;26(4):485-95. doi: 10.1038/modpathol.2012.187. Epub 2012 Dec 7.


p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.

Megha T, Ferrari F, Benvenuto A, Bellan C, Lalinga AV, Lazzi S, Bartolommei S, Cevenini G, Leoncini L, Tosi P.

J Clin Pathol. 2002 Jun;55(6):461-6.


TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer.

Seksenyan A, Kadavallore A, Walts AE, de la Torre B, Berel D, Strom SP, Aliahmad P, Funari VA, Kaye J.

BMC Cancer. 2015 Jan 30;15:22. doi: 10.1186/s12885-015-1018-2.


Dysregulated PTEN-PKB and negative receptor status in human breast cancer.

Shi W, Zhang X, Pintilie M, Ma N, Miller N, Banerjee D, Tsao MS, Mak T, Fyles A, Liu FF.

Int J Cancer. 2003 Mar 20;104(2):195-203.


[Expression of PTEN, p53 and EGFR in the molecular subtypes of breast carcinoma and 
the correlation among them].

Li X, Wang Q, Fu L, Liu M, Yu X.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2015 Sep;40(9):973-8. doi: 10.11817/j.issn.1672-7347.2015.09.005. Chinese.


An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes.

Melchor L, Benítez J.

Carcinogenesis. 2008 Aug;29(8):1475-82. doi: 10.1093/carcin/bgn157. Epub 2008 Jul 1. Review.


Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland.

Shehata M, Teschendorff A, Sharp G, Novcic N, Russell IA, Avril S, Prater M, Eirew P, Caldas C, Watson CJ, Stingl J.

Breast Cancer Res. 2012 Oct 22;14(5):R134. doi: 10.1186/bcr3334.


Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.

Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC.

Breast Cancer Res. 2008;10(4):R67. doi: 10.1186/bcr2128. Epub 2008 Aug 5.


EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice.

Morel AP, Hinkal GW, Thomas C, Fauvet F, Courtois-Cox S, Wierinckx A, Devouassoux-Shisheboran M, Treilleux I, Tissier A, Gras B, Pourchet J, Puisieux I, Browne GJ, Spicer DB, Lachuer J, Ansieau S, Puisieux A.

PLoS Genet. 2012;8(5):e1002723. doi: 10.1371/journal.pgen.1002723. Epub 2012 May 24.


Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas.

O'Leary KA, Rugowski DE, Sullivan R, Schuler LA.

Oncogene. 2014 Jun 5;33(23):3075-82. doi: 10.1038/onc.2013.278. Epub 2013 Jul 22.


Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.

Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, Carvalho FM.

Histopathology. 2009 Sep;55(3):346-52. doi: 10.1111/j.1365-2559.2009.03380.x.


Supplemental Content

Support Center